and AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop ...

Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering. In an SEC filing, Ascentage (AAPG) ...

Carlsbad-based Tyra Biosciences , Inc. announced a change in its Board of Directors, according to a recent SEC filing. On ...

The Oxford-AstraZeneca vaccine is the most potent symbol not just of UK achievement but of collaboration across the sector. Now being used in 170 different countries around the world, it truly is ...

Despite all these challenges, the Israeli health-care system has not only shown the ability to withstand the crisis but also continues to serve as a symbol of coexistence ... Medical Care and ...

The AstraZeneca PLC ADR AZN advanced 2.86% to $70.94 Wednesday, on what proved to be an all-around favorable trading session ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

AstraZeneca PLC closed 15.78% below its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

In substance and timing, AstraZeneca's decision to cancel a planned expansion of its flu vaccine facility at Speke is a blow to the government's recent zeal for growth. Instead of injecting £450m ...

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...